	Roche and Genentech’s Lunsumio-Polivy shows promise in Phase III trial
	Genentech ends ulcerative colitis study for drug from $700 million deal
	Genentech to close cancer immunology research department - Fierce Biotech
	Genentech’s Lunsumio and Polivy Combination Significantly Prolongs Remission for People With Relapsed or Refractory Large B-cell Lymphoma
	Two Biotech Stocks Poised For Big Moves On Monday
	Genentech, a biotech with a storied past, confronts new turbulence in the present
	Genentech expands to North Carolina with $700 million facility, add over 400 new jobs; company based in San Francisco - ABC11 Raleigh-Durham
	Genentech's cancer restructure made 'for scientific reasons'